Skip to main content

Table 1 Cancer type distribution of neoadjuvant and adjuvant anti-PD-1/PD-L1 trials and the comparison among host country

From: The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Cancer type

Host country

China

United States

Rest of world

Total

Non-small-cell lung cancer

39

26

35

100

Breast cancer

10

30

30

70

Esophageal cancer

46

8

6

60

Melanoma

10

41

9

60

Urothelial carcinoma

10

29

20

59

Head and neck squamous cell carcinoma

13

29

14

56

Colorectal cancer

16

13

16

45

Gastric cancer

25

11

8

44

Hepatocellular carcinoma

23

7

6

36

Renal cancer

5

10

4

19

Pancreatic cancer

1

14

4

19

Glioma

3

10

2

15

Soft tissue sarcoma

4

6

2

12

Cutaneous squamous cell carcinoma

1

8

2

11

Mesothelioma

0

11

0

11

Ovarian cancer

0

5

5

10

Solid tumor

0

6

1

7

Biliary tract cancer

4

1

1

6

Prostate cancer

0

5

1

6

Cervical cancer

2

2

0

4

Endometrial carcinoma

0

4

0

4

Merkel cell carcinoma

0

3

1

4

Thyroid cancer

2

1

0

3

Small-cell lung cancer

2

0

0

2

Pancreatic cancer and colorectal cancer

0

1

0

1

Gastric cancer and colorectal cancer

0

0

1

1

NSCLC and HCC

0

1

0

1

NSCLC and Gastric cancer

0

0

1

1

Colorectal cancer and pancreatic cancer

0

1

0

1

Total

216

283

169

668